Incyte CORP Form 4 insider transactions

Baker Bros. Advisors LP and affiliated entities reported transactions involving Incyte Corp common stock, including acquisitions and dispositions.

Paul J. Clancy, a Director at Incyte Corp, acquired 252 shares of common stock on June 30, 2026, as part of a compensation plan.

Baker Bros. Advisors LP and affiliated entities report transactions involving Incyte Corp common stock and stock options, including grants of restricted stock units and non-qualified stock options.

Incyte Corporation director Edmund Harrigan reported transactions involving restricted stock units and stock options.

Incyte Corp. Director Paul J. Clancy acquired 1,642 shares of common stock and exercised a stock option for 6,111 shares.

Incyte Corporation director Jacqualyn A. Fouse acquired restricted stock units and a stock option, as disclosed in a Form 4 filing.

Jean Jacques Bienaime, a Director at Incyte Corp, reported the acquisition of 1,642 shares of common stock and the grant of a non-qualified stock option for 6,111 shares.

Director Katherine A. High of Incyte Corporation has reported the acquisition of restricted stock units and the vesting of stock options.

Thomas Tray of Incyte Corp reported transactions involving common stock and stock options on June 4, 2026.

Pablo Cagnoni of Incyte Corp reports a transaction involving common stock, with shares withheld for tax obligations.

Thomas Tray, Principal Accounting Officer at Incyte Corp, sold 2,051 shares of common stock on May 26, 2026.

Director Jean-Jacques Bienaime exercised 15,000 stock options and sold a portion to cover tax obligations.

Incyte Corporation director Paul J. Clancy reported transactions involving the purchase and sale of common stock and the exercise of a stock option.

Incyte Corporation's CMO, Steven H. Stein, has been awarded 44,124 performance shares based on achieved performance criteria, with vesting scheduled for July 2026.

Incyte Corporation reports that Pablo J. Cagnoni, President, Global Head of R&D, has earned performance shares based on achievement of specified criteria.

Baker Bros. Advisors LP and affiliated entities report transactions involving Incyte Corp. common stock and stock options, reflecting beneficial ownership changes.

Incyte Corp executive Suketu Upadhyay reports on stock awards, restricted stock units, and stock options granted on May 4, 2026.

Pablo Cagnoni, President of Global R&D at Incyte Corp, reported transactions involving the acquisition of common stock and employee stock options.

Incyte Corporation CEO William Meury has earned 125,000 performance-based shares following the achievement of pre-established performance criteria.

Incyte Corporation President and Global Head of R&D Pablo Cagnoni acquired 27,892 shares following the achievement of performance criteria.

Incyte Corporation's Chief Medical Officer Steven H. Stein has been awarded 39,049 shares of common stock following the achievement of performance criteria.

Director Julian C. Baker acquired 421 shares of Incyte Corporation common stock in lieu of quarterly director retainer fees.

Director Paul J. Clancy acquired 265 shares of Incyte Corporation common stock as part of a quarterly director retainer fee election.

Incyte Corp's EVP, GM of Dermatology US, Matteo Trotta, disposed of 537 common shares to cover tax obligations related to restricted stock unit settlement.

Incyte Corp's President of R&D, Pablo J. Cagnoni, exercised stock options and subsequently sold a portion of common stock on March 17, 2026, under a Rule 10b5-1 plan.

Incyte Corp's President of R&D, Pablo J. Cagnoni, exercised stock options and subsequently sold the acquired shares on February 19, 2026, under a pre-arranged plan.

Incyte EVP Michael James Morrissey reported the disposition of 185 common shares for tax withholding purposes at a price of $102.67 per share.

Incyte EVP Lee Heeson reported a disposition of 111 common shares to satisfy tax obligations at a price of $102.67 per share.

Incyte Corp's EVP, Head of Incyte International, Lee Heeson, was granted 8,911 restricted stock units, which will vest 25% annually over four years.

Incyte Corp's President of R&D, Pablo J. Cagnoni, was granted 28,475 employee stock options with an exercise price of $106.21.